Occupational exposure to asbestos is known increase the risk of developing cancer of the lungs (bronchogenic carcinoma) or of the pleura (mesothelioma). Symptoms are subtle and non-specific, diagnosis is often late and the prognosis consequently is dismal. Currently there is no accepted non-invasive tool for the early diagnosis of mesothelioma or lung cancer in asbestos-exposed subjects. In the...
Date First Received: September 12, 2005
Last Updated: October 31, 2007
Verified by: University Health Network, Toronto, October 2007
Clinical Trial Phase: N/A | Start Date: March 2005
Overall Status: Recruiting
Estimated Enrollment: 1000
Brief Summary
Official Title: “Early Diagnosis of Mesothelioma and Lung Cancer Following Asbestos Exposure Using Low-Dose Computed Tomography”
Condition Keyword(s):
Occupational exposure to asbestos is known increase the risk of developing cancer of the lungs (bronchogenic carcinoma) or of the pleura (mesothelioma).
Symptoms are subtle and non-specific, diagnosis is often late and the prognosis consequently is dismal. Currently there is no accepted non-invasive tool for the early diagnosis of mesothelioma or lung cancer in asbestos-exposed subjects. In the last decade, low-dose computed tomography (LDCT) has been successfully developed and validated for the early diagnosis of lung cancer in high-risk smokers. Malignant mesothelioma might, in an early stage, resemble a benign pleural plaque, which is a common finding after asbestos exposure.
We target to develop low-dose CT as a tool to serially image the pleural plaques, quantify their individual and overall volume, compute the growth rate with time, and, as such, identify the presence of mesothelioma early, before symptoms occur.
Study Type: Observational
Study Design: Case Control, Other
Arms, Groups and Cohorts in this Clinical Trial
- : 1
- prior exposure to asbestos
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- prior asbestos exposure at least 20 years ago and/or documented pleural plaques (chest x-ray evidence)
- Resident of Ontario, Canada
Exclusion Criteria:
- prior cancer (except non-melanotic skin cancer)
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 30 Years
Maximum Age for this Clinical Trial: 85 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Sponsor Information
Lead Sponsor: University Health Network, Toronto
Overall Clinical Trial Officials and Contacts
Demetris Patsios, MD Principal Investigator University Health Network, Toronto
Overall Contact: Demetris Patsios, MD Tel: (416) 603-5800 demetris.patsios@uhn.on.ca
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00188890
Study ID Number: Asbestos Screening Study
ClinicalTrials.gov Identifier: NCT00188890
Health Authority: Canada: Health Canada
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
